Triptorelin is a synthetic GnRH agonist used primarily to suppress testosterone in men with advanced prostate cancer, and off-label in conditions ranging from precocious puberty to endometriosis.
What it does
Triptorelin mimics gonadotropin-releasing hormone (GnRH) — the brain signal that tells the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive sex hormone production. The catch is that continuous stimulation does the opposite of what a pulse does. Natural GnRH fires in short bursts; a constant GnRH signal causes the pituitary to downregulate its receptors and essentially stop responding. The result is a sharp, sustained drop in LH, FSH, and ultimately testosterone — a state called medical castration.
In lab comparisons, triptorelin binds pituitary GnRH receptors roughly 20-fold more tightly than natural GnRH and stimulates LH release about 100-fold more potently in isolated rat pituitary cells. In animal studies, triptorelin pamoate (the depot formulation) showed 13-fold higher LH-releasing activity and 21-fold higher FSH-releasing activity than native GnRH. That extra potency makes the initial receptor saturation fast, and the subsequent suppression deep PubMed 2975631.
One important early effect: testosterone briefly spikes in the first one to two weeks before suppression takes hold — a 'flare' that can temporarily worsen symptoms in prostate cancer patients with hormone-sensitive tumors PubMed 8237249. This is why antiandrogens are often co-administered at the start of therapy.
What the evidence shows
Advanced prostate cancer Strong clinical evidence; FDA-approved indication with multiple randomized trials
Triptorelin's approved use is suppressing testosterone in men with advanced prostate cancer, where most tumor cells depend on androgens to grow. A randomized clinical trial found GnRH agonists including triptorelin were superior to surgical castration (subcapsular orchiectomy) in achieving low testosterone levels PubMed 27939836. A separate randomized study compared the metabolic consequences of GnRH agonist therapy versus orchiectomy, confirming comparable hormonal suppression with differing side-effect profiles PubMed 30388320. Long-term depot formulations (3.75 mg monthly, 11.25 mg every three months, 22.5 mg every six months) maintain suppression with similar efficacy and patient convenience PubMed 21847353. Cost-effectiveness analyses in Italy have also modeled the value of LHRH agonists across metastatic prostate cancer settings PubMed 21211489 PubMed 26780073.
Central precocious puberty Clinical evidence supports use; ongoing follow-up studies in pediatric populations
GnRH agonists including triptorelin are used to delay early puberty in children by suppressing the hypothalamic-pituitary-gonadal axis. A follow-up study (NCT00909844) tracked children with precocious puberty treated with triptorelin pamoate to assess long-term hormonal and growth outcomes. This is a recognized off-label and in some countries approved use, though the bulk of the evidence base comes from the broader GnRH agonist class rather than triptorelin-specific trials.
Endometriosis / assisted reproduction Moderate clinical evidence; class-level data with some triptorelin-specific trial data
In women with endometriosis undergoing fertility treatment, prolonged GnRH agonist suppression before intracytoplasmic sperm injection (ICSI) has been investigated to improve outcomes NCT02737800. The rationale is that downregulating estrogen-driven endometrial tissue before stimulation may improve implantation rates, though results across trials have been mixed and the evidence is largely class-level rather than triptorelin-specific.
Anti-doping / pharmacokinetic profiling Investigational; not a therapeutic use case
Triptorelin is on the World Anti-Doping Agency prohibited list because GnRH agonists can be misused to manipulate hormone levels. A study registered under NCT04189900 aimed to generate biological reference samples positive for triptorelin to improve anti-doping detection methods — relevant context for anyone using this compound in athletic settings.
How it's used
In clinical studies and approved prescribing, triptorelin is given as an intramuscular depot injection — not oral or subcutaneous. Depot formulations release the drug slowly over weeks to months. Three dosing intervals are established: 3.75 mg every four weeks, 11.25 mg every 12 weeks, and 22.5 mg every 24 weeks PubMed 21847353 PubMed 22165080. The six-month depot in particular is noted for convenience without sacrificing efficacy. Dose selection depends on the indication and the prescribing clinician's judgment. Because of the testosterone flare in the first one to two weeks, an antiandrogen is typically started a few days before the first injection and continued for several weeks PubMed 8237249. Self-administration outside clinical oversight is not described in the literature for this compound.
Side effects and safety
The most consistently reported effects follow directly from testosterone suppression: hot flashes, decreased libido, fatigue, and mood changes are common across studies PubMed 30388320 PubMed 8237249. Injection site reactions (pain, redness) are mild and transient. Bone density loss is a real concern with long-term use — testosterone is a key driver of bone maintenance in men, and prolonged suppression accelerates bone mineral loss, increasing fracture risk over years PubMed 2975631. Metabolic effects including changes in body composition, insulin sensitivity, and lipid profiles have been documented in randomized comparisons PubMed 30388320. The initial testosterone flare carries clinical risk for patients with vertebral metastases or urinary obstruction. Relative contraindications include pre-existing cardiovascular disease, history of thromboembolism, and osteoporosis — all of which can be worsened by androgen deprivation. Absolute contraindication: known hypersensitivity to triptorelin, other GnRH agonists, or any formulation component. Long-term cardiovascular outcomes of androgen deprivation therapy remain an active area of study, and the full risk profile over decades is not fully characterized.
Bottom line
Triptorelin is a well-characterized, FDA-approved drug with solid clinical trial data for advanced prostate cancer and a clear mechanism of action. Outside its approved indications, evidence is thinner and mostly class-level. The side-effect burden — particularly bone loss and cardiovascular metabolic changes — is real and compounds over time, so this is not a compound to use without direct medical supervision.